A Proof-of-Concept Study Towards Novel ALS Therapy
Verge Genomics, a clinical-stage biotechnology company, has just initiated a Phase 1b proof-of-concept study for VRG50635, a drug developed for … Read More
Verge Genomics, a clinical-stage biotechnology company, has just initiated a Phase 1b proof-of-concept study for VRG50635, a drug developed for … Read More